Question 1

Where does Semax appear in the Selank experiments?

Accepted Answer

Three times, and only one of those is in people. A 2017 rat study is the closest thing to a behavioural head-to-head. It investigated the effects of the synthetic regulatory peptides Semax (analog of an ACTH 4-10 fragment (ACTH4-10)) and Selank (analog of immunomodulatory taftsin) on behavior of rats with 6-hydroxidopamine (6-OHDA) induced PD-like parkinsonism, which is a chemical lesion that kills dopamine nerve cells. On movement the two were alike, and both peptides did not affect motor activity of rats in elevated cross shaped maze and passive defensive behavior of the animals. On anxiety they parted: Selank decreased level of anxiety of rats with toxic damage of DA neurons in elevated cross shaped maze. The second is a dish. A 2017 screen studied the effects of peptide drugs (HLDF-6, PGP, RPGP, and PGLP) and peptide pharmaceutical products (Semax, Selank, and thyroliberin) on proliferation and survival of mouse embryonic stem cells, and there the two separated the other way. Semax (10 and 0.1 μM) significantly increased the survival rate of mouse embryonic stem cells (serum deprivation); Selank is not among the compounds named in that result. The third is a brain scan in 52 people, described further down. One maze, one cell assay and one scanner session is the whole of the direct comparison, and none of them asked a person which compound they preferred.

Question 2

Selank or Semax for anxiety and stress?

Accepted Answer

Anxiety is the outcome Selank was built to move, and it is the one place where a patient comparison exists at all. In a 2008 trial, sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied, and the effect of selank (30 patients) was compared to that of medazepam (32 patients), medazepam being a benzodiazepine. The outcome was a draw with a twist, because the anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. Semax has no comparable patient study among the sources behind this page. The only anxiety measurement covering both compounds is the lesioned-rat maze above, where the change in anxiety belonged to Selank and not to the other arm. That asymmetry is the real answer to which one is better for anxiety. One compound has been put in front of anxious patients against an active comparator three times; the other has been measured on anxiety once, in rats with damaged dopamine cells. That is a difference in how much has been asked rather than a demonstration that one outperforms the other.

Question 3

What has Selank been tested against head to head?

Accepted Answer

Against more compounds than almost any research peptide of its size, and the list is mostly tranquillisers. In patients the rivals are benzodiazepines: medazepam, in the 62-person trial above, and phenazepam twice over. Once head to head, where a study of selank and phenazepam was carried out in 60 patients. Once as an add-on, which set monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) side by side. In animals the rivals are diazepam, in a stress maze and again in a morphine model, and piracetam, in two learning studies. In cells they are GABA, the brain's main calming signal, and the antipsychotic olanzapine. Semax turns up once, in the lesioned-rat maze. Read the list as a map of intent and not of evidence. Selank was built as an anxiolytic, so its rivals came off the anxiolytic shelf. The contest a reader usually wants, against another nootropic peptide, is the one its research programme never ran.

Question 4

How did Selank compare with phenazepam and medazepam?

Accepted Answer

Three patient studies, every one of them set against an active drug rather than a dummy. The 2014 study is the simplest of them. It reports that pronounced anxiolytic and mild nootropic effects of selank were demonstrated, in sixty patients with phobic and somatoform disorders, and that selank had a positive impact on the quality of life of the patients. The 2015 study changed the question from which to both. It ran a benzodiazepine alone against the same benzodiazepine plus the peptide, and found that the positive effect of phenazepam was achieved earlier in the optimization of treatment with selank on HDRS, which is the Hamilton depression rating scale. None of their abstracts reports a placebo arm. Two of the three are indexed as randomised, so the allocation was not the weak point; the comparator was. A design of this shape can show that two compounds look alike, and it cannot show that either does more than the attention around it. That limit applies to every patient result on this page.

Question 5

Does Selank change what diazepam does?

Accepted Answer

Yes, in rats and in brain membranes, and not in the direction a stack implies. A 2017 maze study evaluated the anxiolytic activity of Selank and diazepam in rats both under conditions of unpredictable chronic mild stress and in its absence, after the individual and combined administration of these compounds using the elevated plus maze test. Without chronic stress, the individual administration of Selank was the most effective in reducing elevated levels of anxiety. With it, the combination of diazepam with Selank was the most effective in reducing anxiety in unpredictable chronic mild stress conditions. Which arm came out ahead depended on whether the animals had been stressed at all. A withdrawal model ranks them the other way. In morphine-dependent rats, Selank was slightly inferior to diazepam in a dose of 2 mg/kg by pharmacological activity. The receptor work explains why none of this adds up neatly. A 2018 study reports that the joint action of Selank and some of benzodiazepines also regulates activity of [3H]GABA binding in specific manner, which is not cumulative and differs from either substance individually. Not cumulative is the phrase to hold on to, because two compounds working on one receptor can interfere as readily as they can add.

Question 6

What happened when Selank was compared with piracetam?

Accepted Answer

Twice, in rats learning to avoid a shock, and the interesting part is the size of the dose gap. In the 2003 report, the effects of Selank (300 microg/kg) were compared with the effects of the nootrope piracetam (400 mg/kg). That is roughly a thousandfold difference in material for a comparable task, which is the kind of number that gets lost when two compounds are listed side by side as nootropics. The 2002 Russian-language report of the same work puts the result carefully. Some distinguishing features were revealed in the dynamics of activatory effects of Selank and Pyracetam, meaning the two curves were not the same shape even where the endpoints matched. Both papers also show where the gain sat. The maximum optimizing activity of Selank on learning in normal rats was seen on day 3 of repeated administration and training, which is later and smaller than in the animals that began as poor learners. The Semax side of the nootropic comparison is set out at the Semax comparison page.

Question 7

Can you use Selank and Semax together?

Accepted Answer

The pair has not been given together in any study among the sources behind this page. What has been measured is Selank in company with other compounds, and those results argue against assuming that effects simply add. In cells, a 2017 experiment found that the combined effect of GABA and Selank led to nearly complete suppression of changes in expression of genes in which mRNA levels changed under the effect of GABA. Adding the peptide cancelled most of what GABA had done alone. A different pairing went the opposite way. When Selank was used in conjunction with olanzapine, the expression alterations of more genes were observed compared with olanzapine alone. So across these sources, adding a second compound to Selank has cancelled an effect, amplified an effect, and depended on whether the animals were stressed. Three directions from three pairings is a statement about what has been asked rather than a basis for predicting a fourth, and a Semax pairing would be that fourth.

Question 8

How long can you stay on Selank and Semax?

Accepted Answer

The published courses are short, and none of them is a course of both compounds. In patients, the longest exposure among these sources is two weeks. A 2008 immune study followed patients with generalized anxiety disorder and neurasthenia who received Selank during 14 days. The add-on trial ran alongside a benzodiazepine and then past it, reporting effects during the course of treatment and after the tranquilizer withdrawal. In animals the runs are shorter still. One route comparison gave heptapeptide selank (300 μg/kg/day for 5 days), and the learning studies dosed with repeated administration of peptide 15 min before the start of training sessions for four days. No study among the sources behind this page has run Selank and Semax as a single course, in people or in animals. A duration for the pair would therefore be an invention rather than a report, and the two compounds' own published courses are not the same length to begin with.

Question 9

How long does it take for Selank and Semax to kick in?

Accepted Answer

Onset was measured once for the pair, and it was measured with a scanner rather than with a question. The 52-person imaging study scanned each participant before the injection, five minutes after it and twenty minutes after it. At those points between-group alongwith between-condition differences were revealed in FC between the right amygdala and a region in fusiform, inferior and middle temporal as well as parahippocampal gyri in the right hemisphere, where FC means functional connectivity. Twenty minutes is fast, and what moved was a correlation between brain regions rather than a feeling anyone reported. In animals the timing is built into the protocol instead of being an outcome. The learning experiments gave the peptide fifteen minutes before each training session, which assumes rather than demonstrates that fifteen minutes is long enough. In patients, nothing in these sources reports a time to first effect. The trials measured state at the end of a course, which answers a different question from the one a reader asking about onset is actually asking.

Question 10

What side effects are recorded for the Selank and Semax pair?

Accepted Answer

For the pair, nothing is recorded, because the pair has not been given. For Selank alone, side effects were recorded on a formal scale, which is unusual in this field. The 2015 add-on trial used a dedicated instrument, and reports that tolerability was evaluated using the UKU scale, a checklist used in psychiatry. What it recorded was a reduction in the comparator's problems rather than a list of the peptide's own: in those patients the combined treatment decreased the level of undesirable side-effects of phenazepam, which the paper itemises as attention and memory impairment, asthenia, sedation, increase in sleep duration, sexual disturbances, emotional indifference and orthostatism. An older paper describes Selank as a peptide which attenuates behavioral anxiety reactions and does not cause side effects typical of most anxiolytics. That is the authors' summary rather than a measured finding, and it should be read as a claim being made rather than as a result being reported. The one study that tested both compounds for harm looked at cells. Our results indicate that these peptide compounds do not produce toxic effect during the embryonic and fetal period of life, it concludes, having measured mouse embryonic stem cells in a dish. That is the weakest place a statement about harm can come from, and it is the only place this pair has one.

Question 11

What is the Selank and Semax blend?

Accepted Answer

A blend is a product description rather than a studied preparation, and no analysis of a mixed Selank and Semax preparation appears among the sources behind this page. What the literature holds is the two compounds given separately inside one experiment, which is a different thing. The 52-person scan injected either Semax, or Selank, or placebo, one per session, and the lesioned-rat study dosed each peptide as its own arm. There is a reason the pairing looks plausible on paper. A 2026 orthopaedic review groups them by mechanism, writing that neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity. BDNF is the growth factor a nerve cell needs in order to survive. Two compounds said to push the same growth factor might add, might overlap, or might do neither. The only direct evidence about combining Selank with anything found an effect that is not cumulative, and that is the sentence to carry into any question about a blend.

Question 12

Does the nasal route change what Selank does?

Accepted Answer

It changed what the peptide bound to, in mice. A 2016 study compared pharmacological effects of intraperitoneal (i.p.) and intranasal (i.n.) administration of heptapeptide selank, where intraperitoneal means injected into the abdominal cavity. Behaviourally the routes looked alike, since the anxiolytic and nootropic efficiency of selank administered via both routes was observed only in BALB/c mice, the strain that started out more anxious. Underneath, the two routes were doing different things. In BALB/c mice, i.p. selank increased the number of [G-(3)H]SR 95531 binding sites with GABA-receptors in the frontal cortex by 38%, without change in binding to NMDA receptors in the hippocampus. The nasal route did the opposite, and i.n. selank led to an increase in the density of [G-(3)H]MK-801 binding sites by 23% with no effect on GABA receptors. Two routes, two receptor systems, one behaviour. That is a reason to read a nasal spray and an injection as different exposures rather than as packaging, and no study among the sources behind this page has repeated the comparison in a person.

Question 13

How does the Selank evidence stand against the Semax evidence?

Accepted Answer

On patient numbers Selank is ahead. On controls, both are thin. Selank has three patient comparisons against an active drug, with 62, 60 and 70 people in them, plus two further patient studies measuring a blood enzyme and immune signals. One of those enzyme results is a mechanism claim rather than an outcome: selank was more potent than peptidase inhibitors bacitracin and puromycin in inhibiting enkephalinases, measured in plasma. The place both compounds sit in one design is the 52-person scan. It has a placebo arm, which none of the patient trials covered here report, and it measures a brain image rather than a symptom. That is the strongest design on either side attached to the weakest outcome. A 2026 review covering both records a current lack of clinical trials, which is the field's own verdict rather than ours. More comparisons does not mean better evidence either. Selank has been compared more often because it was built as an anxiolytic and there was an obvious shelf to compare it against, and the Semax record is set out at the Semax comparison page.

Question 14

What does Selank share with tuftsin and its own fragments?

Accepted Answer

Selank is a tuftsin analogue, and the comparisons inside its own family are the quietest and most useful in this literature. A 2017 review of the parent molecule sets the scene. An example of such a substance is tuftsin (TKPA), it says, and its analogs were divided because of their anti-tumor, anti-inflammatory, antimicrobial and anti-viral activity. None of those four headings is anxiety, which is a useful reminder that Selank comes from an immune family and not a psychiatric one. The fragment comparison sharpens it. A 2014 experiment studied the effect of Selank and its short fragment Gly-Pro on the temporary dynamics of C3, Casp1, Il2rg, and Xcr1 genes expression in mouse spleen, four immune genes, and found that in most cases, there was a coincidence in the expression profiles of the studied genes after Selank and Gly-Pro administration. A two-residue fragment reproducing most of the parent molecule's gene response is awkward for any comparison built on the whole peptide. It suggests part of what Selank does is not specific to Selank, which is a different problem from the one a reader comparing it with Semax came to solve. The matching fragment work on Semax is set out at the Semax comparison page.

Route	GABA-receptor binding sites, frontal cortex	NMDA-receptor binding
Injected into the abdominal cavity (i.p.)	Up 38%	No change (hippocampus)
Intranasal (i.n.)	No effect	Binding-site density up 23%

Selank comparisons and stacks